<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150408</url>
  </required_header>
  <id_info>
    <org_study_id>2013-27</org_study_id>
    <nct_id>NCT02150408</nct_id>
  </id_info>
  <brief_title>Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors</brief_title>
  <acronym>DOTATATENET</acronym>
  <official_title>Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastro-Entero-Pancreatic tumors (GEPs) are a subset of Neuroendocrine tumors (NETs) derived
      from the primitive gut and include digestive and bronchial NETs.

      Historically, the gold standard in their functional exploration is the &quot;conventional&quot;
      somatostatin receptors scintigraphy (SRS) labeled with Indium-111 (Octreoscan®). This
      reference imaging is complementary to Tomography (CT) and liver MRI. However SRS sensitivity
      is moderate (60 %), because of its intrinsic detection limits, which could delay the
      diagnosis or lead to inappropriate therapy.

      The use of somatostatin agonists (DOTATOC, DOTATATE, DOTANOC), radiolabeled with gallium-68
      (68Ga) enables targeting of Somatostatin receptors (SSTRs) with a PET resolution. This has
      improved diagnosis of TNE with a gain in sensitivity of over 20% compared to SRS.
      Furthermore, patient irradiation and imaging protocol are significantly reduced.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging</measure>
    <time_frame>12-15 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT</measure>
    <time_frame>12-15 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT</measure>
    <time_frame>12-15 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastro-Entero-Pancreatic Tumors (GEPs)</condition>
  <arm_group>
    <arm_group_label>assesment by 68Ga-DOTATATE PET-CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET-CT</intervention_name>
    <arm_group_label>assesment by 68Ga-DOTATATE PET-CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age ≥ 18,

               -  Patient with one of the following situations : suspicion of GEP, initial staging
                  of non-metastatic GEP, GEP with unknown primary tumor, Restaging of GEP
                  justifying focused therapeutic approach

               -  Reference imaging within the last 3 months: multiphasic thoracoabdominal CT
                  scan, liver MRI and SRS (SPECT/CT).

        Exclusion Criteria:

          -  Pregnant or breast-feeding woman

          -  Other cancer disease

          -  GEP with grade 3 tumours

          -  Non GEP TNE (paragangliome, medullar thyroid cancer)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David TAIEB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David TAIEB, MD</last_name>
    <phone>33491384406</phone>
    <email>dtaieb@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David TAIEB, MD</last_name>
      <phone>33491384406</phone>
      <email>dtaieb@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>David TAIEB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
